Recent Finacing
Recent Raise
Monopar Therapeutics acquires and licenses oncology drugs from late preclinical to advanced clinical stages, developing GPX-150 (non-cardiotoxic anthracycline), Phase III-ready Validive clonidine mucobuccal tablet, and uPAR-targeting MNPR-101.
Focus Areas
Total Raised
Funding round